Toborzás még nem indult3. fázis
A Phase 3 Study of CBP501 + Cisplatin + Nivolumab versus Physician’s Choice of Therapy for ≥3rd Line Treatment of Patients with Advanced Pancreatic Adenocarcinoma [FUJI-PanC01]
A legfontosabb adatok
- Ki végzi
- Canbas Co. Ltd.
- Hol
- Franciaország9 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toborzás még nem indult
- Fázis
- 3. fázis
- Résztvevők
- 30 fő, tervezett
- Kezdés
- 2027. jan. 29.
- Várható befejezés
- 2029. jan. 31.
- A vizsgálat típusa
- Beavatkozással járó
- A regiszteradat frissítve
- 2026. november 18.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 33 feltétel megnézéseKevesebb
Ki vehet részt
- Signed informed consent obtained prior to initiation of any study-specific procedures and treatment; 10 Ability to cooperate with study treatment and follow-up
- Patients with pathologically confirmed stage IV pancreatic adenocarcinoma who have received at least two lines of systemic therapy for advanced disease. Up to 4 prior lines of systemic therapy are allowed, including prior cisplatin or investigational agents, with the exception that a patient must not have received more than two prior lines incorporating anti-PD-1, anti-PD-L1, or anti-CTLA-4 immune checkpoint blockade. Patients who have received prior anti-PD-1, anti-PD-L1, or anti-CTLA-4 immune checkpoint blockade therapy must have tolerated therapy with no evidence of grade ≥3 toxicity or an immune-related event (any grade) that required treatment discontinuation. Patients who experienced an endocrine related dysfunction are eligible, provided they are on stable hormone replacement therapy
- Male or female patients aged ≥ 18 years at time of informed consent
- ECOG Performance Status (PS) 0-1
- Life expectancy > 3 months
- Previous anticancer treatment must be discontinued at least 3 weeks prior to the initiation of study treatment (with the exception of 6 weeks for mitomycin C; 6 weeks for anti-androgen therapy if discontinued prior to treatment initiation, and 8 weeks for bicalutamide); 7 Adequate bone marrow reserve, cardiac, liver, renal and metabolic function: - absolute neutrophil count (ANC) ≥ 1,500/mm3; - platelet count ≥ 100,000/mm3; - hemoglobin ≥ 9 g/dL; - creatinine phosphokinase CPK ≤ upper limit of normal (ULN); - serum troponin T levels within normal limits; - bilirubin ≤ 1.5 x ULN; - alanine aminotransferase (ALT, SGPT) and aspartate aminotransferase (AST, SGOT) ≤ 2.5 x ULN (≤ 5 x ULN if liver metastases are present); - INR ≤ 1.5 x ULN; or INR < 3 x ULN for anticoagulated patients; - serum creatinine ≤ ULN and creatinine clearance ≥ 60 mL/min (by Cockroft & Gault formula or alternate calculation by 24hr urine collection).; - serum potassium ≥ 3.0 and ≤ 5.5 mmol/L; - serum calcium ≥ 8.0 and ≤ 11.5 mg/dL (≥ 2.0 and ≤ 2.9 mmol/L); - serum magnesium ≥ 1.2 and ≤ 3.0 mg/dL (≥ 0.5 and ≤ 1.23 mmol/L)
- Female patients of child-bearing potential must have a negative serum or highly sensitive urine pregnancy test and use a highly effective form of contraception as approved by the Investigator (e.g., physical contraception, hormonal birth control, intrauterine device (IUD)) for 4 weeks prior to initiating study treatment and for at least 5 half-lives after the last dose of each study drug or longer period specified in drug labeling (e.g., 5 months for nivolumab, 6 months for capecitabine, gemcitabine and 5FU, 7 months for liposomal irinotecan, 14 months for cisplatin and CBP501, and 15 months for oxaliplatin). Pregnancy testing must be performed monthly throughout the study and for at least the applicable period after the end of treatment with each study drug. For the purposes of this study, child-bearing potential is defined as all female patients unless they are post-menopausal for at least 3 years or surgically sterile
- Male patients must use a form of barrier contraception approved by the Investigator during the study and for at least 5 half-lives after the last dose of each study drug or longer period specified in drug labeling (e.g., 11 months for cisplatin and CBP501, 12 months for oxaliplatin, 4 months for liposomal irinotecan, and 3 months for fluorouracil, capecitabine or gemcitabine)
Ki nem vehet részt
- 1 Presence of any serious concomitant systemic disorders incompatible with the study in the opinion of the investigator (e.g., uncontrolled congestive heart failure, active infection, etc.)
- 7 Active CNS metastases; however, patients with CNS metastases will be eligible if they have been treated and are stable without symptoms for 4 weeks after completion of treatment, with image documentation required, and must be off steroids
- 8 Who require chronic systemic steroid therapy or are on any other form of immunosuppressive medication
- 16 Persistent toxicities grade >1 associated with prior treatment
- 25 Patients with contraindications to the drugs of treatment regimen chosen for the patient for the control arm (arm 2), according to the SmPC of these products, especially section 4.3 of the SmPC
- 9 Has received a live-virus vaccination within 30 days of planned treatment start
- 19 Receiving systemic steroid therapy (>10 mg daily prednisone or equivalent)
- 13 Patients who were permanently discontinued from prior immunotherapy due to immune-related adverse events
- 3 Presence of any significant central nervous system (CNS) or psychiatric disorder(s) that would hamper the patient’s compliance
- 6 Known HIV, HBV, or HCV infection (excluding cured HBV and/or cured HCV infection)
- 24 Hypersensitivity to CBP501 (no excipients in CBP501 Infusion)
- 20 History of uncontrolled or symptomatic cardiac disease
- 21 History of anterior organ transplant, including stem cell allograft
- 10 With known risk factors for bowel perforation, e.g., intra-abdominal abscess, intestinal obstruction, or extensive abdominal carcinomatosis within 6 months of study entry, or history of diverticulitis
- 11 Has an active autoimmune disease or a documented history of autoimmune disease
- 12 Has a history pneumonitis or interstitial lung disease
- 2 Any previous history of another malignancy (other than cured basal cell or squamous cell carcinoma of the skin or cured in-situ carcinoma) within 5 years of study entry
- 15 Patients with QT/QTc interval > 450 msec in men and >470 msec in women
- 22 Hypersensitivity to cisplatin or any of the excipients in cisplatin, i.e., sodium chloride
- 23 Hypersensitivity to nivolumab or any of the excipients in nivolumab, i.e., sodium citrate dihydrate, sodium chloride, mannitol, pentetic acid, polysorbate 80
- 17 Taking phenytoin with prophylactic aim
- 5 Pregnant or breast-feeding patients or any patient with child-bearing potential not using adequate contraception
- 18 Cardiorespiratory pathology which forbids a hyperhydration
- 4 Evidence of peripheral neuropathy grade ≥ 2
- 14 Patients with hearing loss or hearing issues
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Evaluate overall survival (OS) Determine whether there is a statistically significant difference in OS between CBP501/cisplatin/nivolumab therapy (Triplet, arm1) versus physician’s choice of therapy (Control, arm 2) in the ITT population.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- A Phase 3, Open-Label, Multicenter, Randomized Study of a Combination of CBP501, Cisplatin and Nivolumab or Physician’s Choice of Therapy for ≥3rd Line Treatment of Patients with Advanced Pancreatic Adenocarcinoma
- A regiszteradat frissítve
- 2026. november 18.